BCB
NVO

Brian C. Broderick’s Novo Nordisk NVO Stock Holding History

Brian C. Broderick’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$204K Sell
5,545
-590
-10% -$28K 0.04% 91
2025
Q4 		$312K Sell
6,135
-29,866
-83% -$1.53M 0.06% 75
2025
Q3 		$2M Sell
36,001
-5,060
-12% -$296K 0.38% 45
2025
Q2 		$2.83M Buy
41,061
+8,350
+26% +$568K 0.56% 39
2025
Q1 		$2.27M Buy
32,711
+26,795
+453% +$2.21M 0.46% 42
2024
Q4 		$509K Sell
5,916
-175
-3% -$18.9K 0.1% 64
2024
Q3 		$725K Sell
6,091
-349
-5% -$46.5K 0.14% 61
2024
Q2 		$919K Sell
6,440
-355
-5% -$47K 0.19% 59
2024
Q1 		$872K Sell
6,795
-885
-12% -$105K 0.19% 63
2023
Q4 		$794K Sell
7,680
-450
-6% -$44.5K 0.2% 54
2023
Q3 		$739K Sell
8,130
-490
-6% -$43.2K 0.2% 54
2023
Q2 		$697K Sell
8,620
-200
-2% -$16.3K 0.18% 53
2023
Q1 		$702K Sell
8,820
-250
-3% -$17.7K 0.2% 55
2022
Q4 		$614K Hold
9,070
– – 0.18% 57
2022
Q3 		$452K Sell
9,070
-330
-4% -$17.7K 0.14% 58
2022
Q2 		$524K Sell
9,400
-200
-2% -$11.1K 0.16% 57
2022
Q1 		$533K Sell
9,600
-370
-4% -$19K 0.14% 59
2021
Q4 		$558K Buy
9,970
+1,820
+22% +$98.6K 0.13% 58
2021
Q3 		$391K Sell
8,150
-400
-5% -$19.3K 0.1% 61
2021
Q2 		$358K Sell
8,550
-100
-1% -$3.88K 0.1% 62
2021
Q1 		$292K Sell
8,650
-150
-2% -$5.34K 0.08% 65
2020
Q4 		$308K Sell
8,800
-250
-3% -$8.64K 0.09% 64
2020
Q3 		$314K Hold
9,050
– – 0.1% 67
2020
Q2 		$296K Sell
9,050
-450
-5% -$14.4K 0.1% 73
2020
Q1 		$286K Sell
9,500
-50
-0.5% -$1.49K 0.11% 69
2019
Q4 		$276K Hold
9,550
– – 0.09% 72
2019
Q3 		$247K Sell
9,550
-200
-2% -$5.06K 0.09% 76
2019
Q2 		$248K Sell
9,750
-230
-2% -$5.68K 0.09% 76
2019
Q1 		$261K Sell
9,980
-300
-3% -$7.37K 0.09% 72
2018
Q4 		$237K Hold
10,280
– – 0.1% 74
2018
Q3 		$242K Hold
10,280
– – 0.08% 79
2018
Q2 		$237K Sell
10,280
-900
-8% -$21.4K 0.09% 79
2018
Q1 		$275K Sell
11,180
-470
-4% -$12.3K 0.1% 77
2017
Q4 		$313K Sell
11,650
-320
-3% -$8.14K 0.11% 75
2017
Q3 		$288K Sell
11,970
-412
-3% -$9.31K 0.1% 86
2017
Q2 		$266K Sell
12,382
-630
-5% -$12.7K 0.1% 88
2017
Q1 		$223K Sell
13,012
-828
-6% -$14.4K 0.09% 89
2016
Q4 		$247K Sell
13,840
-2,660
-16% -$48.2K 0.11% 87
2016
Q3 		$343K Hold
16,500
– – 0.15% 81
2016
Q2 		$444K Buy
16,500
+850
+5% +$23.3K 0.19% 74
2016
Q1 		$424K Buy
+15,650
New +$419K 0.18% 77

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Brian C. Broderick's NVO Position: Q1 2026 in Review

Brian C. Broderick reduced its Novo Nordisk (NVO) stake by 9.6% in Q1 2026, selling an estimated $28K and leaving 5,545 shares worth $204K. The position accounts for 0.04% of the portfolio, ranked #91.

Brian C. Broderick first reported a position in NVO in Q1 2016 and has held it in 41 quarters since. The position peaked at $2.83M in Q2 2025. 1,271 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Brian C. Broderick held 5,545 shares of Novo Nordisk worth $204K as of Q1 2026.
  • Brian C. Broderick sold 590 Novo Nordisk shares in Q1 2026, an estimated $28K.
  • Novo Nordisk made up 0.04% of Brian C. Broderick's portfolio in Q1 2026, its #91 holding.
  • Brian C. Broderick first reported a position in Novo Nordisk in Q1 2016 and has held it in 41 quarters since.
  • Brian C. Broderick's Novo Nordisk position peaked at $2.83M in Q2 2025.
  • 1,271 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Brian C. Broderick's 13F filing for Q1 2026, filed 7 May 2026.